Adolfsson J
Abteilung für Urologie, Karolinska-Krankenhaus, Stockholm, Schweden.
Urologe A. 1996 Nov;35(6):454-5. doi: 10.1007/s001200050051.
From 1978 to 1982, 172 patients with T1-3, Nx, M0 prostate cancer were included in a surveillance protocol with deferred treatment on symptomatic progression. The median age at diagnosis was 68 (38-89) years. The disease-specific survival at 10 years was 80% for the total series, 84% for the subgroup with T1-2 tumors, and 92% for patients with T1-2 tumors diagnosed when the patients were old less than 70 years. For the subgroup with T3 tumors, the disease-specific survival at 9 years was 70%. In all subgroups the competing mortality was higher than the prostate cancer mortality. Deferred treatment appears to be an acceptable treatment option for patients with a tumor clinically confined to the prostate with a life expectancy of 10 years or less.
1978年至1982年，172例T1 - 3、Nx、M0期前列腺癌患者被纳入一项监测方案，在出现症状进展时延迟治疗。诊断时的中位年龄为68（38 - 89）岁。整个系列的10年疾病特异性生存率为80%，T1 - 2期肿瘤亚组为84%，70岁以下确诊T1 - 2期肿瘤的患者为92%。对于T3期肿瘤亚组，9年疾病特异性生存率为70%。在所有亚组中，竞争性死亡率高于前列腺癌死亡率。对于临床局限于前列腺且预期寿命为10年或更短的患者，延迟治疗似乎是一种可接受的治疗选择。
